Floatz logo

CTAP-101

Hyperparathyroidism, Secondary

OPKO Health, Inc.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hyperparathyroidism, Secondary cohort.

Asset / SponsorPhaseRating
VITAMIN D
University of Sao Paulo General Hospital
Phase 4BB

Same molecule, other indications

CTAP-101 is also rated in:

bone neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
Bartter syndrome with hypocalcemiaDormant
CC
Indicative ·
47 / 100
View asset →
breast cancerDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →